AstraZeneca takes a chance on the STING pathway with F-star

After a slew of Big Pharma companies and biotechs walked away from the STING pathway in the last few years, AstraZeneca is approaching the field with a new bet on the drug class’ next generation.

The British drugmaker is teaming up with F-star Therapeutics on a slate of preclinical STING...

Click to view original post